Literature DB >> 24167266

Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.

Meghan R Perry1, Susan Wyllie, Andrea Raab, Joerg Feldmann, Alan H Fairlamb.   

Abstract

The Indian subcontinent is the only region where arsenic contamination of drinking water coexists with widespread resistance to antimonial drugs that are used to treat the parasitic disease visceral leishmaniasis. We have previously proposed that selection for parasite resistance within visceral leishmaniasis patients who have been exposed to trivalent arsenic results in cross-resistance to the related metalloid antimony, present in the pentavalent state as a complex in drugs such as sodium stibogluconate (Pentostam) and meglumine antimonate (Glucantime). To test this hypothesis, Leishmania donovani was serially passaged in mice exposed to arsenic in drinking water at environmentally relevant levels (10 or 100 ppm). Arsenic accumulation in organs and other tissues was proportional to the level of exposure and similar to that previously reported in human liver biopsies. After five monthly passages in mice exposed to arsenic, isolated parasites were found to be completely refractory to 500 μg · mL(-1) Pentostam compared with the control passage group (38.5 μg · mL(-1)) cultured in vitro in mouse peritoneal macrophages. Reassessment of resistant parasites following further passage for 4 mo in mice without arsenic exposure showed that resistance was stable. Treatment of infected mice with Pentostam confirmed that resistance observed in vitro also occurred in vivo. We conclude that arsenic contamination may have played a significant role in the development of Leishmania antimonial resistance in Bihar because inadequate treatment with antimonial drugs is not exclusive to India, whereas widespread antimonial resistance is.

Entities:  

Keywords:  drug resistance; environmental pollution; sodium antimony gluconate; treatment failure

Mesh:

Substances:

Year:  2013        PMID: 24167266      PMCID: PMC3856816          DOI: 10.1073/pnas.1311535110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

Review 1.  Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

Authors:  François Chappuis; Shyam Sundar; Asrat Hailu; Hashim Ghalib; Suman Rijal; Rosanna W Peeling; Jorge Alvar; Marleen Boelaert
Journal:  Nat Rev Microbiol       Date:  2007-11       Impact factor: 60.633

2.  Management of visceral leishmaniasis in rural primary health care services in Bihar, India.

Authors:  E Hasker; S P Singh; P Malaviya; R P Singh; R Shankar; M Boelaert; S Sundar
Journal:  Trop Med Int Health       Date:  2010-07       Impact factor: 2.622

Review 3.  Role of metabolism in arsenic toxicity.

Authors:  M Vahter; G Concha
Journal:  Pharmacol Toxicol       Date:  2001-07

4.  Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?

Authors:  Suman Rijal; Vanessa Yardley; François Chappuis; Saskia Decuypere; Basudha Khanal; Rupa Singh; Marleen Boelaert; Simonne De Doncker; Simon Croft; Jean-Claude Dujardin
Journal:  Microbes Infect       Date:  2007-01-27       Impact factor: 2.700

Review 5.  Leishmaniasis.

Authors:  B L Herwaldt
Journal:  Lancet       Date:  1999-10-02       Impact factor: 79.321

6.  In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.

Authors:  Karin Seifert; Patricia Escobar; Simon L Croft
Journal:  J Antimicrob Chemother       Date:  2010-01-20       Impact factor: 5.790

7.  Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.

Authors:  Alejandro Llanos-Cuentas; Gianfranco Tulliano; Roger Araujo-Castillo; Cesar Miranda-Verastegui; Giovanna Santamaria-Castrellon; Luis Ramirez; Marcela Lazo; Simonne De Doncker; Marleen Boelaert; Jo Robays; Jean-Claude Dujardin; Jorge Arevalo; Francois Chappuis
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

8.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

9.  Assessment of lymphocyte subpopulations and cytokine secretion in children exposed to arsenic.

Authors:  Gerson A Soto-Peña; Ana L Luna; Leonor Acosta-Saavedra; Patricia Conde; Lizbeth López-Carrillo; Mariano E Cebrián; Mariana Bastida; Emma S Calderón-Aranda; Libia Vega
Journal:  FASEB J       Date:  2006-02-06       Impact factor: 5.191

10.  Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden.

Authors:  Manu Vanaerschot; Simonne De Doncker; Suman Rijal; Louis Maes; Jean-Claude Dujardin; Saskia Decuypere
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

View more
  25 in total

1.  Chronic arsenic exposure and microbial drug resistance.

Authors:  Malcolm J McConville; Stuart A Ralph
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-13       Impact factor: 11.205

Review 2.  The genetics of Leishmania virulence.

Authors:  Eugenia Bifeld; Joachim Clos
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

Review 3.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

4.  Transmission potential of antimony-resistant leishmania field isolates.

Authors:  Veronika Seblova; Bruno Oury; Naouel Eddaikra; Khatima Aït-Oudhia; Francine Pratlong; Elodie Gazanion; Carla Maia; Petr Volf; Denis Sereno
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

5.  Arsenic silences hepatic PDK4 expression through activation of histone H3K9 methylatransferase G9a.

Authors:  Xi Zhang; Jianguo Wu; Jonathan Choiniere; Zhihong Yang; Yi Huang; Jason Bennett; Li Wang
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-20       Impact factor: 4.219

6.  A Multiplatform Metabolomic Approach to the Basis of Antimonial Action and Resistance in Leishmania infantum.

Authors:  David Rojo; Gisele A B Canuto; Emerson A Castilho-Martins; Marina F M Tavares; Coral Barbas; Ángeles López-Gonzálvez; Luis Rivas
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

7.  Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study.

Authors:  Meghan R Perry; Vijay K Prajapati; Joris Menten; Andrea Raab; Joerg Feldmann; Dipankar Chakraborti; Shyam Sundar; Alan H Fairlamb; Marleen Boelaert; Albert Picado
Journal:  PLoS Negl Trop Dis       Date:  2015-03-02

8.  Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study.

Authors:  Sushmita Das; Rakesh Mandal; Vidya Nand Rabidas; Neena Verma; Krishna Pandey; Ashok Kumar Ghosh; Sreekant Kesari; Ashish Kumar; Bidyut Purkait; Chandra Sekhar Lal; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2016-10-24

9.  Oral exposure to arsenic causes hearing loss in young people aged 12-29 years and in young mice.

Authors:  Xiang Li; Nobutaka Ohgami; Yasuhiro Omata; Ichiro Yajima; Machiko Iida; Reina Oshino; Shoko Ohnuma; Nazmul Ahsan; Anwarul Azim Akhand; Masashi Kato
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

Review 10.  Drug resistance in eukaryotic microorganisms.

Authors:  Alan H Fairlamb; Neil A R Gow; Keith R Matthews; Andrew P Waters
Journal:  Nat Microbiol       Date:  2016-06-24       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.